In the past, viral hepatitis, particularly types B and C, were the predominant causes of liver injury progressing to severe liver conditions such as cirrhosis or HCC. The advent of effective treatments for hepatitis C and preventative measures including vaccines for hepatitis B sparked a global public health response. As nations began to implement widespread screening, vaccination programs, and treatment protocols, the rates of new infections began to decline. Public policy and regulatory frameworks were adapted to facilitate these changes, improving access to care and treatment for affected populations.

Despite the progress made in combating viral hepatitis, there is a pressing need to focus on SLD, which has emerged as the leading risk indicator for liver-related morbidity and mortality. Unlike viral hepatitis infections, which can be identified through targeted testing, SLD often remains undetected due to its asymptomatic progression. This necessitates a paradigm shift in the approach to screening, where proactive case finding becomes crucial. However, current efforts in SLD screening and early diagnosis lag significantly behind the condition’s rising prevalence.

Patients with SLD represent a diverse population, comprised of individuals affected by various factors including metabolic syndrome, obesity, diabetes, and alcohol consumption. These intertwined risk factors create a complex landscape that complicates diagnosis and intervention. Unlike viral hepatitis, where clear guidelines and testing strategies exist, the spectrum of SLD lacks standardized screening protocols, which could potentially identify at-risk individuals before the onset of serious complications.

The public health community has learned valuable lessons from the historical context of viral hepatitis management. These lessons point towards the necessity for legal and regulatory frameworks that enhance public health infrastructures. The creation and integration of targeted screening programs and increased access to testing are imperative for the effective management of SLD. Legislative measures should aim to facilitate early management strategies while expanding the availability of health services to vulnerable populations.

Moreover, public awareness campaigns can play a pivotal role in changing perceptions regarding liver health. Informing individuals about risk factors associated with SLD and encouraging them to seek medical advice can be instrumental in reducing the incidence of advanced liver disease. These campaigns should target not only the general population but also healthcare professionals, emphasizing the critical importance of liver health surveillance.

As we shift focus towards SLD, partnerships across various sectors including healthcare, public policy, and community organizations will be essential. These collaborations can aid in the development of innovative strategies that emphasize the importance of early detection and intervention. Incorporating a multi-disciplinary approach, where healthcare providers, policymakers, and the community work in unison, can lead to effective and sustainable solutions for combating the rising tide of SLD.

The ongoing evolution of healthcare policy in response to the challenges posed by liver diseases underscores the need for adaptable strategies. As our understanding of SLD matures, so too must our frameworks for addressing it. Developing an evidence-based policy response is vital for ensuring that interventions can be tailored to meet the specific needs of affected populations.

Equally, the integration of technological advancements into healthcare frameworks can provide new avenues for managing liver diseases. Utilizing electronic health records to flag at-risk patients, leveraging artificial intelligence for predictive analytics, and promoting telehealth services can enhance accessibility to testing and treatment. These technological interventions could significantly augment early diagnosis and foster a more proactive healthcare environment.

As the field progresses, continued research into SLD is necessary for gaining deeper insights into pathophysiology, screening methodologies, and treatment options. By building a robust evidence base, we can inform policy decisions that prioritize effective interventions for those at risk. Translating this knowledge into actionable policies will be critical for curbing the rising burden of liver disease globally.

In conclusion, it is evident that the evolving landscape of liver diseases requires urgent attention. As we learn from past successes in the management of viral hepatitis, a concerted effort must be made to enhance our responses to SLD. This entails not only legal and regulatory reforms but also a holistic approach that encompasses public education, technological integration, and collaborative efforts across sectors. By addressing these fundamental issues, we can work toward improving health outcomes and ultimately reducing the burden of liver diseases on individuals and society.

The time to act is now. Acknowledging that SLD stands as a significant health threat is the first step towards implementing effective screening and intervention strategies. Together, we can bring about change that prioritizes liver health and improves lives across the globe.

Subject of Research: Steatotic Liver Disease and Policy Responses

Article Title: Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease

Article References: Lazarus, J.V., Kopka, C.J., Nicolàs, A. et al. Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease. Nat Rev Gastroenterol Hepatol (2026). https://doi.org/10.1038/s41575-026-01174-z

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01174-z

Keywords: Steatotic Liver Disease, Viral Hepatitis, Public Health Policy, Screening, Healthcare Access

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a pervasive yet covert threat, currently afflicting approximately one-third of adults worldwide. This prevalence underscores the necessity for heightened awareness and early detection strategies. Within this spectrum lies metabolic dysfunction-associated steatohepatitis (MASH), a more aggressive variant that affects approximately 5% of the general population but often evades clinical identification until irreversible liver damage, such as cirrhosis or hepatocellular carcinoma, has ensued. The silent progression of MASH, particularly among individuals displaying risk factors such as type 2 diabetes and obesity, challenges existing paradigms of liver disease management and necessitates a shift towards preemptive medical intervention.

Compelling scientific discourse emerged alongside the simultaneous publication in The Lancet Regional Health – Europe, where eminent hepatology and metabolic researchers advocated for a transformative objective: to double the diagnosis rate of MASH by the year 2027. This ambitious target recognizes the gap between disease burden and clinical recognition, illuminating the pressing need for innovative diagnostic approaches. Early identification holds the promise of intercepting disease progression, enabling timely therapeutic intervention that could substantially reduce morbidity, mortality, and the overarching healthcare costs attributed to advanced liver pathology.

Central to this diagnostic revolution is the integration of non-invasive modalities and artificial intelligence (AI)-driven technologies. Techniques such as transient elastography, controlled attenuation parameter (CAP) imaging, and serum biomarker panels are emerging as frontline tools capable of stratifying risk with minimal patient burden. Coupled with AI algorithms trained on vast clinical datasets, these methods enhance predictive accuracy, optimize resource allocation, and facilitate their deployment within primary care settings where early interaction with at-risk populations frequently occurs. This synergy between technology and clinical practice heralds a new era of accessibility and efficiency in liver disease diagnostics.

Furthermore, the therapeutic landscape for MASLD and MASH is rapidly evolving, marked by the recent approval of a novel pharmacological agent demonstrating efficacy in halting or reversing inflammatory and fibrotic processes within the liver. This advancement amplifies the imperative for timely diagnosis, as access to effective treatment is now a tangible reality rather than a distant goal. Medical leaders emphasize that treatment innovations, however promising, must be paired with comprehensive screening and diagnostic frameworks to maximize patient outcomes and alleviate the burgeoning public health burden.

Achieving a paradigm shift by 2030 demands a cohesive and multifaceted strategy. Experts propose embedding routine liver disease screening protocols within existing health check-up regimens, particularly targeting individuals with established metabolic risk factors. Such integration warrants recalibration of healthcare policies, including reimbursement mechanisms that incentivize primary care practitioners to adopt liver testing algorithms proactively. Multidisciplinary collaboration transcending hepatology to include endocrinology, cardiology, and patient advocacy groups is pivotal to crafting resilient care pathways tailored to diverse patient populations.

Authors and leaders, including Dr. Jeffrey Lazarus of ISGlobal’s Public Health Liver Group, emphasize the critical transition from reactive to preventive hepatology. The future of liver disease management hinges on anticipation—not merely addressing patients with advanced fibrosis but systematically identifying and managing those at an earlier, asymptomatic stage. This preventive approach could profoundly impact global metabolic health, reducing progression rates and ultimately mitigating the associated societal and economic tolls.

Concurrently, the Global Think-tank has spotlighted the imperative to reformulate the discourse surrounding liver disease through the People-First Liver Charter, recently published in Nature Medicine. This groundbreaking initiative challenges stigmatizing terminology and advocates for language that foregrounds the individual rather than clinical labels. The charter’s person-centred care framework is designed to foster dignity, respect, and equity within healthcare interactions, recognizing that stigma and discrimination frequently delay diagnosis and treatment, thereby exacerbating disease outcomes. Endorsed by more than 70 organizations worldwide, this movement seeks to recalibrate societal and clinical perceptions, fostering more compassionate, inclusive health environments.

The evolving epidemiology of liver disease in Spain exemplifies the broader global trends. Data reveal a concerning escalation; in 2021, the Spanish population living with MASLD numbered approximately eight million, with projections indicating a surge to 12.7 million individuals—over a quarter of the nation’s population—by 2030. MASH cases are expected to climb from 1.8 million in 2016 to 2.7 million by the end of the decade. Correspondingly, mortality attributable to MASH is forecasted to double, reaching nearly 7,600 deaths annually, with healthcare expenditures exceeding $3.5 billion by 2040, more than doubling current costs. This data compels urgent policy reforms and systemic responses.

Spain’s response, as urged by Dr. Lazarus, involves the development of a comprehensive national strategy under the stewardship of the Ministry of Health, collaborating closely with autonomous regional authorities. Key components include the establishment of a MASLD registry, integration of MASLD metrics into core health indicators, augmented training programs for healthcare workers, implementation of automated diagnostic tools in primary care, and bolstering community-based support services. Such an approach would position Spain as a potential leader in addressing this escalating challenge, providing a model for other nations grappling with similar epidemics.

Despite its enormous prevalence—estimated to affect over 1.5 billion people globally—chronic liver disease has largely been marginalized within the broader umbrella of non-communicable diseases (NCDs). This oversight represents a critical gap in both global health policy and clinical practice. With the United Nations High-Level Meeting on NCDs scheduled for September 2025, the experts convened in Barcelona have called emphatically for this historical neglect to be rectified. Integrating chronic liver diseases into global health agendas and national NCD frameworks is essential for securing resources, guiding policy, and galvanizing coordinated international efforts.

The intersection of emerging technology, novel therapeutics, comprehensive policy, and stigma reduction forms a multifaceted battlefront against MASLD and MASH. This urgent campaign demands not only medical innovation but also systemic commitment to transforming care delivery landscapes. Only through early diagnosis, inclusive language, targeted public health strategies, and interdisciplinary collaboration can this silent epidemic be unveiled, addressed, and ultimately curtailed.

As the global community stands at this critical juncture, the imperative is clear: embrace a proactive, anticipatory, and person-centred approach to metabolic liver diseases. Doing so promises a future where millions are spared the devastating consequences of advanced liver pathology, healthcare systems mitigate unsustainable burdens, and affected individuals reclaim dignity and quality of life. The window for transformative action is now, and the stakes could not be higher.

Subject of Research: People

Article Title: A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

News Publication Date: June 5, 2025

Web References:

• Global Think-tank on Steatotic Liver Disease: https://sldthinktank.com/
• The Lancet Regional Health Europe article: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00112-7/fulltext
• People-First Liver Charter: https://www.nature.com/articles/s41591-025-03759-8
• MASLD/MASH in Spain Policy Brief: https://sldthinktank.com/policy_and_insights/masld-mash-in-spain-a-liver-health-policy-brief/

References:

• Lazarus, Jeffrey V. et al. "A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis." The Lancet Regional Health – Europe, 2025.
• Lazarus, J.V., Ivancovsky Wajcman, D., Pannain, S., et al. "The People-First Liver Charter." Nature Medicine, 2025.

Keywords: Liver damage, Steatohepatitis, Artificial intelligence, Medical diagnosis